CN105353127B - A kind of composition that can detect kinds of tumors and its application - Google Patents
A kind of composition that can detect kinds of tumors and its application Download PDFInfo
- Publication number
- CN105353127B CN105353127B CN201510789097.3A CN201510789097A CN105353127B CN 105353127 B CN105353127 B CN 105353127B CN 201510789097 A CN201510789097 A CN 201510789097A CN 105353127 B CN105353127 B CN 105353127B
- Authority
- CN
- China
- Prior art keywords
- antibody
- label
- specific antigen
- collaurum
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/559—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Abstract
It is disclosed by the invention it is a kind of can detect the composition of kinds of tumors, participate in immune turbidity reaction as antibody carrier, available for detection kinds of tumors, substantially increase the sensitivity of detection.It is described to detect the composition of kinds of tumors, it is made up of antibody, polymer, the colloidal gold solution of a variety of identification tumour specific antigens；Its preparation method is：By the antibody of a variety of identification tumour specific antigens respectively with after colloid gold label, the copolymer of the antibody of different tumour specific antigens is recognized from polymer formation being used for comprising a variety of colloid gold labels, it is re-used as antibody carrier and participates in immune turbidity reaction, Immune-enhancing effect external diagnosis reagent for detecting kinds of tumors, detectable kinds of tumors, with general applicability, and the sensitivity of detection is higher.
Description
Technical field
The present invention relates to technical field of medical examination, be specifically related to a kind of composition that can detect kinds of tumors and its
Using.
Background technology
Tumour has become one of important diseases of serious harm human life and health, the incidence of disease of whole world malignant tumour
With the death rate in the trend risen year by year.And the sustained growth impetus is presented in the tumour related to ecological environment, life style.
And there is no effective medicine, especially late period for tumour.Therefore, the early detection of tumour and diagnosis, for tumour
Treatment has key effect.
At present, the clinical diagnosis Main Basiss of tumour are examined in the clinical manifestation of patient, various imageological examinations and laboratory
Survey technology.But, clinically many cancer patients have no obvious symptom in early stage, have often been reached an advanced stage during discovery.It is various
Iconography detection technique, such as x-ray, B ultrasound, CT, magnetic resonance, as important tumour auxiliary diagnosis means, can not generally also find
Less infantile tumour is not high to early carcinoma of stomach diagnostic value.
With the progress of Protocols in Molecular Biology, increasing tumor marker is found, available for the detection of tumour,
And specificity and sensitivity are also fine.These biological detection methods include immunoturbidimetry, enzyme linked immunological hair, fluorescence labeling
Method etc., wherein, latex Immunity transmission turbidity is to adsorb antibody on a kind of latex particle, when running into corresponding antigen,
Antigen-antibody combines and latex agglutination occurs.The size of single latex particle is within incident wavelength, light-transmissive, when two
During the latex particle agglutination of the above, light can be hindered to pass through so that transmitted light is reduced, it reduces the amount of degree and antigen into just
Than.This method improves the sensitivity and the degree of accuracy of detection, is widely used.However, Immunoturbidimetry is anti-
Ying Houhui produces precipitation, is unfavorable for the cleaning of biochemical instruments, interference test result, and latex manufacturing cost is higher, causes immune ratio
Turbid kit price and testing cost are higher.Therefore the immunoturbidimetry of nano-particle reinforcement is occurred in that again, but it is applied
There is certain limitation, therefore, need scientific research person's further expansion in this respect.
The content of the invention
Present invention solves the technical problem that be to provide it is a kind of can detect the composition of kinds of tumors, join as antibody carrier
Plus immune turbidity reaction, available for detection kinds of tumors, substantially increase the sensitivity of detection.
The technical scheme is that：As claimed in claim 1, it is a kind of to detect the composition of kinds of tumors, be by
Antibody, polymer, the colloidal gold solution composition of a variety of identification tumour specific antigens；Its preparation method is：By a variety of knowledges
With after colloid gold label, a variety of colloid gold labels are included with polymer formation respectively for the antibody of other tumour specific antigen
For the copolymer for the antibody for recognizing different tumour specific antigens.
Further, being used for comprising a variety of colloid gold labels is recognized to the antibody of different tumour specific antigens
Copolymer participates in immune turbidity reaction as antibody carrier, can as the Immune-enhancing effect external diagnosis reagent for detecting kinds of tumors,
The sensitivity of detection is substantially increased, and available for the detection of kinds of tumors.
Further, the polymer is biodegradable polymer, and its biocompatibility preferably, is also allowed at the later stage
Reason.
Further, the biodegradable polymer is selected from poly- hydroxacetic acid, poly butyric ester, lactic acid-poly- second
Any one in diol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl alcohol ester.
Further, the tumour includes stomach cancer, liver cancer, colon cancer, naturally it is also possible to be other Cancerous diseases.
Further, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；It is described
For recognizing that the antibody of liver cancer-specific antigen is human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize that colon cancer is special
Property antigen antibody be the antibody of colon cancer antigen 3 (SDCCAG3).
Further, the antibody copolymer preparation method of the identification tumour specific antigen of the nano gold mark is：
(1) colloidal gold solution is prepared：Trisodium citrate aqueous solution and mass percent with mass percent concentration for 1%
Concentration is 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, lemon by chlorauric acid solution
Sour three sodium water solutions are rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, 10min is reheated, until solution
It is bright, it is cooled to room temperature, the wet chemical for being then 0.05~0.1mol/L with concentration regulation pH value is 6.5~8.0, is produced
Colloidal gold solution；
(2) in the colloidal gold solution obtained by step (1), concentration is slowly added under magnetic stirring for 10~50 μ g/mL
Be used for recognize the antibody aqueous solution of stomach cancer specific antigen, mix, 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubations
20~22min is centrifuged under the conditions of 22~25min, 14000rpm, 4 DEG C, supernatant is removed, dilution, which is resuspended, precipitates and wash one
It is secondary, obtain collaurum-anti-S100P protein polyclone antibodies label I；
The another colloidal gold solution taken obtained by step (1), is slowly added to the use that concentration is 10~50 μ g/mL under magnetic stirring
In the antibody aqueous solution of identification liver cancer-specific antigen, marked according to the above-mentioned collaurum-anti-S100P protein polyclone antibodies that prepare
The same operating method of thing I, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II；
The another colloidal gold solution taken obtained by step (1), is slowly added to the use that concentration is 10~50 μ g/mL under magnetic stirring
In the antibody aqueous solution of identification colon cancer specific antigen, collaurum-anti-S100P protein polyclone antibody marks are prepared according to above-mentioned
Remember the same operating method of thing I, obtain the antibody of collaurum-colon cancer antigen 3 (SDCCAG3) label III；
(3) polymer is pressed 1:18~30 weight ratio is dissolved in dichloromethane, adds the obtained mark of above-mentioned steps (2)
Remember thing I, label II, label III, with 30~60s of ultrasonication, obtain the identification stomach cancer, liver cancer, knot of colloid gold label
The antibody copolymer of the specific antigen of three kinds of tumours of intestinal cancer.
Further, described collaurum-anti-S100P protein polyclone antibodies label I, is calculated, i.e. glue in mass ratio
Body gold:Anti- S100P protein polyclone antibodies are 5:0.21~0.23；Described collaurum-human liver cancer tissue AFU polyclonal antibodies
Label II, is calculated in mass ratio, i.e. collaurum:Human liver cancer tissue AFU polyclonal antibodies are 5:0.25~0.28；Described glue
Body gold-the antibody of colon cancer antigen 3 (SDCCAG3) label III, is calculated, i.e. collaurum in mass ratio:The antibody of colon cancer antigen 3
(SDCCAG3) it is 5:0.23~0.26.
Further, the frequency of the ultrasonication is 35~55KHz, can make the polymerization to be formed through ultrasonication
Thing is uniform.
Further, the confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 0.3~1mg/mL, plus
Non-specific binding can be avoided by entering confining liquid.
The beneficial effects of the invention are as follows：By the way that the antibody of a variety of identification tumour specific antigens is used into colloid gold label respectively
Afterwards, being used for comprising a variety of colloid gold labels recognizes the anti-of different tumour specific antigens from biodegradable polymer formation
The copolymer of body, participates in immune turbidity reaction, for detecting that the Immune-enhancing effect in-vitro diagnosis of kinds of tumors is tried as antibody carrier
Agent, can detect kinds of tumors, with general applicability；Relative to various iconography detection techniques of the prior art, such as x-ray, B
For the important tumour auxiliary diagnosis means such as super, CT, magnetic resonance, the purpose of early diagnosis can be reached, and is compared to existing
Some immune turbidimetries, also substantially increase the sensitivity of detection.
Embodiment
Embodiment 1：
It is a kind of to detect the composition of stomach cancer, liver cancer, colon cancer, it is by for recognizing the anti-of stomach cancer specific antigen
Body, the antibody for recognizing liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer, collaurum
Solution composition；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；It is described to use
In identification liver cancer-specific antigen antibody be human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize colon cancer specificity
The antibody of antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, selected from poly- hydroxyl
Base acetic acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl
Any one in alcohol ester, the biodegradable polymer biological compatibility of these classes preferably, also allows for post-processing.
The antibody copolymer preparation method of the identification tumour specific antigen of the nano gold mark is：
(1) colloidal gold solution is prepared：Trisodium citrate aqueous solution and mass percent with mass percent concentration for 1%
Concentration is 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, lemon by chlorauric acid solution
Sour three sodium water solutions are rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, 10min is reheated, until solution
It is bright, it is cooled to room temperature, the wet chemical for being then 0.05mol/L with concentration regulation pH value is 6.5, produces collaurum molten
Liquid；
(2) in the colloidal gold solution obtained by step (1), the use that concentration is 10 μ g/mL is slowly added under magnetic stirring
In the antibody aqueous solution of identification stomach cancer specific antigen, mix, 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubations
22min, the confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 0.3mg/mL, and adding confining liquid can avoid
Non-specific binding, then 14000rpm, 20min is centrifuged under the conditions of 4 DEG C, removes supernatant, and dilution, which is resuspended, precipitates and wash one
It is secondary, collaurum-anti-S100P protein polyclone antibodies label I is obtained, is calculated in mass ratio, collaurum:Anti- S100P albumen is more
Clonal antibody is 5:0.21；
The another colloidal gold solution taken obtained by step (1), is slowly added to the use that concentration is 10~50 μ g/mL under magnetic stirring
In the antibody aqueous solution of identification liver cancer-specific antigen, marked according to the above-mentioned collaurum-anti-S100P protein polyclone antibodies that prepare
The same operating method of thing I, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculates in mass ratio, glue
Body gold:Human liver cancer tissue AFU polyclonal antibodies are 5:0.25；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 10 μ g/mL be used for know
The antibody aqueous solution of other colon cancer specific antigen, collaurum-anti-S100P protein polyclone antibody labels are prepared according to above-mentioned
I same operating method, obtains the antibody of collaurum-colon cancer antigen 3 (SDCCAG3) label III, calculates in mass ratio, colloid
Gold:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.23；
(3) polymer is pressed 1:18 weight ratio is dissolved in dichloromethane, adds label made from above-mentioned steps (2)
Ith, label II, label III, use ultrasonication 30s, the frequency of the ultrasonication is 35KHz, through ultrasonication
The polymer uniform to be formed can be made, the specificity for obtaining the identification stomach cancer, liver cancer, three kinds of tumours of colon cancer of colloid gold label resists
Former antibody copolymer.
By the identification stomach cancer of the colloid gold label, liver cancer, the specific antigen of three kinds of tumours of colon cancer antibody copolymerization
Thing participates in immune turbidity reaction as antibody carrier, is tried as detection stomach cancer, liver cancer, the Immune-enhancing effect in-vitro diagnosis of colon cancer
Agent, substantially increases the sensitivity of detection.
Embodiment 2：
It is a kind of to detect the composition of stomach cancer, liver cancer, colon cancer, it is by for recognizing the anti-of stomach cancer specific antigen
Body, the antibody for recognizing liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer, collaurum
Solution composition；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；It is described to use
In identification liver cancer-specific antigen antibody be human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize colon cancer specificity
The antibody of antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, selected from poly- hydroxyl
Base acetic acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl
Any one in alcohol ester, the biodegradable polymer biological compatibility of these classes preferably, also allows for post-processing.
The antibody copolymer preparation method of the identification tumour specific antigen of the nano gold mark is：
(1) colloidal gold solution is prepared：Trisodium citrate aqueous solution and mass percent with mass percent concentration for 1%
Concentration is 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, lemon by chlorauric acid solution
Sour three sodium water solutions are rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, 10min is reheated, until solution
It is bright, it is cooled to room temperature, the wet chemical for being then 0.075mol/L with concentration regulation pH value is 7.0, produces collaurum molten
Liquid；
(2) in the colloidal gold solution obtained by step (1), the use that concentration is 30 μ g/mL is slowly added under magnetic stirring
In the antibody aqueous solution of identification stomach cancer specific antigen, mix, 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubations
23.5min, the confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 0.65mg/mL, and adding confining liquid can keep away
Exempt to centrifuge 21min under the conditions of non-specific binding, then 14000rpm, 4 DEG C, remove supernatant, dilution, which is resuspended, to be precipitated and wash
Once, collaurum-anti-S100P protein polyclone antibodies label I is obtained, is calculated in mass ratio, collaurum:Anti- S100P albumen
Polyclonal antibody is 5:0.22；
The another colloidal gold solution taken obtained by step (1), is slowly added to the use that concentration is 10~50 μ g/mL under magnetic stirring
In the antibody aqueous solution of identification liver cancer-specific antigen, marked according to the above-mentioned collaurum-anti-S100P protein polyclone antibodies that prepare
The same operating method of thing I, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculates in mass ratio, glue
Body gold:Human liver cancer tissue AFU polyclonal antibodies are 5:0.265；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 30 μ g/mL be used for know
The antibody aqueous solution of other colon cancer specific antigen, collaurum-anti-S100P protein polyclone antibody labels are prepared according to above-mentioned
I same operating method, obtains the antibody of collaurum-colon cancer antigen 3 (SDCCAG3) label III, calculates in mass ratio, colloid
Gold:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.245；
(3) polymer is pressed 1:24 weight ratio is dissolved in dichloromethane, adds label made from above-mentioned steps (2)
Ith, label II, label III, use ultrasonication 45s, the frequency of the ultrasonication is 35~55KHz, through ultrasonic wave
Processing can make the polymer uniform to be formed, obtain colloid gold label three kinds of tumours of identification stomach cancer, liver cancer, colon cancer it is special
The antibody copolymer of property antigen.
By the identification stomach cancer of the colloid gold label, liver cancer, the specific antigen of three kinds of tumours of colon cancer antibody copolymerization
Thing participates in immune turbidity reaction as antibody carrier, is tried as detection stomach cancer, liver cancer, the Immune-enhancing effect in-vitro diagnosis of colon cancer
Agent, substantially increases the sensitivity of detection.
Embodiment 3：
It is a kind of to detect the composition of stomach cancer, liver cancer, colon cancer, it is by for recognizing the anti-of stomach cancer specific antigen
Body, the antibody for recognizing liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer, collaurum
Solution composition；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；It is described to use
In identification liver cancer-specific antigen antibody be human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize colon cancer specificity
The antibody of antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, selected from poly- hydroxyl
Base acetic acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl
Any one in alcohol ester, the biodegradable polymer biological compatibility of these classes preferably, also allows for post-processing.
The antibody copolymer preparation method of the identification tumour specific antigen of the nano gold mark is：
(1) colloidal gold solution is prepared：Trisodium citrate aqueous solution and mass percent with mass percent concentration for 1%
Concentration is 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, lemon by chlorauric acid solution
Sour three sodium water solutions are rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, 10min is reheated, until solution
It is bright, it is cooled to room temperature, the wet chemical for being then 0.1mol/L with concentration regulation pH value is 8.0, produces colloidal gold solution；
(2) in the colloidal gold solution obtained by step (1), concentration is slowly added under magnetic stirring for 10~50 μ g/mL
Be used for recognize the antibody aqueous solution of stomach cancer specific antigen, mix, 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubations
25min, the confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 1mg/mL, and addition confining liquid can avoid non-
Specific binding, then 14000rpm centrifuges 22min under the conditions of 4 DEG C, removes supernatant, dilution is resuspended to precipitate and simultaneously washed once,
Collaurum-anti-S100P protein polyclone antibodies label I is obtained, is calculated in mass ratio, collaurum:Anti- S100P protein polyclones
Antibody is 5:0.23；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 50 μ g/mL be used for know
The antibody aqueous solution of other liver cancer-specific antigen, collaurum-anti-S100P protein polyclone antibodies label I is prepared according to above-mentioned
Same operating method, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculates in mass ratio, colloid
Gold:Human liver cancer tissue AFU polyclonal antibodies are 5:0.28；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 50 μ g/mL be used for know
The antibody aqueous solution of other colon cancer specific antigen, collaurum-anti-S100P protein polyclone antibody labels are prepared according to above-mentioned
I same operating method, obtains the antibody of collaurum-colon cancer antigen 3 (SDCCAG3) label III, calculates in mass ratio, colloid
Gold:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.26；
(3) polymer is pressed 1:30 weight ratio is dissolved in dichloromethane, adds label made from above-mentioned steps (2)
Ith, label II, label III, use ultrasonication 60s, the frequency of the ultrasonication is 55KHz, through ultrasonication
The polymer uniform to be formed can be made, the specificity for obtaining the identification stomach cancer, liver cancer, three kinds of tumours of colon cancer of colloid gold label resists
Former antibody copolymer.
By the identification stomach cancer of the colloid gold label, liver cancer, the specific antigen of three kinds of tumours of colon cancer antibody copolymerization
Thing participates in immune turbidity reaction as antibody carrier, is tried as detection stomach cancer, liver cancer, the Immune-enhancing effect in-vitro diagnosis of colon cancer
Agent, substantially increases the sensitivity of detection.
Experimental data
1st, experimental subjects：
Stomach cancer, liver cancer, colorectal cancer patients totally 900 that certain hospital accepts for medical treatment from January, 2009 in December, 2010 are selected, its
Middle patients with gastric cancer 300, liver cancer patient 300, colorectal cancer patients 300, all equal initial diagnosis of case be stomach cancer, liver cancer or
Colon cancer, and do not received radiation and chemotherapy before.
2nd, detection reagent：
Identification stomach cancer, liver cancer, the specificity of three kinds of tumours of colon cancer of colloid gold label prepared by the embodiment of the present invention 1
The antibody copolymer of antigen as detection reagent I, the identification stomach cancer of colloid gold label prepared by the embodiment of the present invention 2, liver cancer,
The antibody copolymer of the specific antigen of three kinds of tumours of colon cancer is as detection reagent II, glue prepared by the embodiment of the present invention 3
Body gold mark identification stomach cancer, liver cancer, the antibody copolymer of the specific antigen of three kinds of tumours of colon cancer as detection reagent III,
The serum of above-mentioned 900 patients is gathered respectively, is used as testing sample.
3rd, experimental method：
Packet：Above-mentioned 300 patients with gastric cancer, 300 liver cancer patients, 300 colorectal cancer patients are divided into 3 respectively
Group, every group of each 100 people, is designated as respectively：1 group of stomach cancer, 2 groups of stomach cancer, 3 groups of stomach cancer, 1 group of liver cancer, 2 groups of liver cancer, 3 groups of liver cancer, colon
1 group of cancer, 2 groups of colon cancer, 3 groups of colon cancer.1 group of stomach cancer, 1 group of liver cancer, 1 group of colon cancer detected using detection reagent I, stomach cancer
2 groups, 2 groups of liver cancer, 2 groups of colon cancer detected that stomach cancer 3,3 groups of liver cancer, 3 groups of colon cancer use detection examination using detection reagent II
Agent III is detected.
Detection method：Gastric cancer antigen is extracted in Serum Obtained From Advance Gastric Cancer respectively, liver cancer is extracted in liver cancer patient blood serum and is resisted
Original, extracts colon cancer antigen in colorectal cancer patients serum, and dilution respectively obtains 1.0 μ g/L of concentration difference, 7.5 μ g/L, 15 μ g/
L, 30 μ g/L, 60 μ g/L, 120 μ g/L sample to be tested.The blank absorbency OD0 of first detection reagent, using 6 calibrating methods,
The corresponding μ L of each group patients serum sample 10 are separately added into every 500ul detection reagents, mixing is mixed, the two is occurred antigen and resist
Precursor reactant, puts 37 DEG C, after being incubated 3 hours, and it is 6 groups of absorbances of correspondence at 340nm to read wavelength by spectrophotometer
OD1、OD2、OD3、OD4、OD5、OD6。
Detecting instrument：OLYMPUS AU640 automatic clinical chemistry analyzers.
4th, data statistics result is detected：
Detect that positive 298,300 liver cancer patients detect positive 296,300 colons in 300 patients with gastric cancer
Cancer, which is suffered from, detects the positive 299, and total recall rate is 99.2%.
5th, conclusion：The present invention is used to detect that the composition of kinds of tumors can to detect kinds of tumors, and sensitivity is high, recall rate
It is high.
Finally it should be noted that：The above embodiments are merely illustrative of the technical solutions of the present invention, rather than its limitations；Although
The present invention is described in detail with reference to the foregoing embodiments, it will be understood by those within the art that：It still may be used
To be modified to the technical scheme described in previous embodiment, or equivalent substitution is carried out to which part technical characteristic；And
These modifications are replaced, and the essence of appropriate technical solution is departed from the spirit and model of technical scheme of the embodiment of the present invention
Enclose.
Claims (4)
1. a kind of can detect the composition of kinds of tumors, it is characterised in that be by the anti-of a variety of identification tumour specific antigens
Body, polymer, colloidal gold solution composition；Its preparation method is：By the antibody difference of a variety of identification tumour specific antigens
After colloid gold label, different tumour specific antigens are recognized from polymer formation being used for comprising a variety of colloid gold labels
Antibody copolymer；By being total to for the antibody for recognizing different tumour specific antigens comprising a variety of colloid gold labels
Polymers participates in immune turbidity reaction as antibody carrier, can be used as the Immune-enhancing effect external diagnosis reagent for detecting kinds of tumors；Institute
Polymer is stated for biodegradable polymer；The biodegradable polymer is selected from poly- hydroxacetic acid, poly butyric
Any one in ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl alcohol ester；
The tumour includes stomach cancer, liver cancer, colon cancer；It is described to be used to recognize that the antibody of stomach cancer specific antigen is more for anti-S100P albumen
Clonal antibody；The antibody for being used to recognize liver cancer-specific antigen is human liver cancer tissue AFU polyclonal antibodies；It is described to be used to know
The antibody of other colon cancer specific antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The identification tumour of the colloid gold label is special
The antibody copolymer preparation method of Specific Antigen is：
(1) colloidal gold solution is prepared：With the trisodium citrate aqueous solution and mass percent concentration that mass percent concentration is 1%
For 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, citric acid three by chlorauric acid solution
Sodium water solution is rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, is cooled to room temperature, is then adjusted pH value and is
6.5~8.0, produce colloidal gold solution；
(2) it is slowly added to concentration being used for for 10~50 μ g/mL under magnetic stirring in the colloidal gold solution obtained by step (1)
The antibody aqueous solution of stomach cancer specific antigen is recognized, is mixed, 37 DEG C of incubation 30min, plus 37 DEG C of incubations 22 of confining liquid continuation~
20~22min is centrifuged under the conditions of 25min, 14000rpm, 4 DEG C, supernatant is removed, dilution, which is resuspended, to be precipitated and washed once, and is obtained
To collaurum-anti-S100P protein polyclone antibodies label I；
The another colloidal gold solution taken obtained by step (1), addition concentration is 10~50 μ g/mL for recognizing liver cancer-specific antigen
The antibody aqueous solution, prepare collaurum-same operating method of anti-S100P protein polyclone antibodies label I according to above-mentioned, obtain
To collaurum-human liver cancer tissue AFU polyclonal antibodies label II；
The another colloidal gold solution taken obtained by step (1), addition concentration is 10~50 μ g/mL for recognizing that colon cancer specificity is anti-
The former antibody aqueous solution, collaurum-same operating method of anti-S100P protein polyclone antibodies label I is prepared according to above-mentioned,
Obtain the antibody of collaurum-colon cancer antigen 3 (SDCCAG3) label III；
(3) polymer is dissolved in dichloromethane, adds label I, label II, label made from above-mentioned steps (2)
III, with 30~60s of ultrasonication, the specificity for obtaining the identification stomach cancer, liver cancer, three kinds of tumours of colon cancer of colloid gold label resists
Former antibody copolymer；Described collaurum-anti-S100P protein polyclone antibodies label I, is calculated, i.e. colloid in mass ratio
Gold:Anti- S100P protein polyclone antibodies are 5:0.21~0.23；Described collaurum-human liver cancer tissue AFU polyclonal antibody marks
Remember thing II, calculate in mass ratio, i.e. collaurum:Human liver cancer tissue AFU polyclonal antibodies are 5:0.25~0.28；Described colloid
The antibody of gold-colon cancer antigen 3 (SDCCAG3) label III, is calculated, i.e. collaurum in mass ratio:The antibody of colon cancer antigen 3
(SDCCAG3) it is 5:0.23~0.26；The frequency of the ultrasonication is 35~55KHz；The confining liquid is containing cow's serum
The cleaning solution of albumen, its mass concentration is 0.3~1mg/mL.
2. a kind of can detect the composition of stomach cancer, liver cancer, colon cancer, be by the antibody for recognizing stomach cancer specific antigen,
For recognizing the antibody of liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer, colloidal gold solution
Composition；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；It is described to be used to know
The antibody of other liver cancer-specific antigen is human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize colon cancer specific antigen
Antibody be the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, selected from poly- hydroxyl vinegar
Acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxy alkyl alcohol ester
In any one；
The antibody copolymer preparation method of the identification tumour specific antigen of the colloid gold label is：
(1) colloidal gold solution is prepared：With the trisodium citrate aqueous solution and mass percent concentration that mass percent concentration is 1%
For 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, citric acid three by chlorauric acid solution
Sodium water solution is rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, reheats 10min, until solution is bright,
It is cooled to room temperature, the wet chemical for being then 0.05mol/L with concentration regulation pH value is 6.5, produces colloidal gold solution；
(2) in the colloidal gold solution obtained by step (1), be slowly added under magnetic stirring concentration for 10 μ g/mL be used for know
The antibody aqueous solution of other stomach cancer specific antigen, is mixed, and 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubation 22min, institute
Confining liquid is stated for the cleaning solution containing bovine serum albumin, its mass concentration is 0.3mg/mL, non-specificity can be avoided by adding confining liquid
With reference to, then 14000rpm, 20min is centrifuged under the conditions of 4 DEG C, supernatant is removed, dilution is resuspended to precipitate and simultaneously washed once, and obtains glue
Body gold-anti-S100P protein polyclone antibodies label I, is calculated, collaurum in mass ratio:Anti- S100P protein polyclone antibodies are
5:0.21；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 10~50 μ g/mL be used for know
The antibody aqueous solution of other liver cancer-specific antigen, collaurum-anti-S100P protein polyclone antibodies label I is prepared according to above-mentioned
Same operating method, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculates in mass ratio, colloid
Gold:Human liver cancer tissue AFU polyclonal antibodies are 5:0.25；The another colloidal gold solution taken obtained by step (1), delays under magnetic stirring
The slow antibody aqueous solution for being used to recognize colon cancer specific antigen for adding concentration for 10 μ g/mL, according to it is above-mentioned prepare collaurum-
The same operating method of anti-S100P protein polyclone antibodies label I, obtains the antibody of collaurum-colon cancer antigen 3
(SDCCAG3) label III, calculates in mass ratio, collaurum:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.23；(3) will
The polymer presses 1:18 weight ratio is dissolved in dichloromethane, adds label I made from above-mentioned steps (2), label II, mark
Remember thing III, use ultrasonication 30s, the frequency of the ultrasonication is 35KHz, can make what is formed to gather through ultrasonication
Compound is uniform, obtains the identification stomach cancer, liver cancer, the antibody copolymerization of the specific antigen of three kinds of tumours of colon cancer of colloid gold label
Thing.
3. a kind of can detect the composition of stomach cancer, liver cancer, colon cancer, it is characterised in that by for recognizing stomach cancer specific antigen
Antibody, the antibody for recognizing liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer, glue
Body gold solution is constituted；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；Institute
It is human liver cancer tissue AFU polyclonal antibodies to state the antibody for recognizing liver cancer-specific antigen；It is described to be used to recognize that colon cancer is special
The antibody of Specific Antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, is selected from
Poly- hydroxacetic acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxyl
Any one in alkyl alcohol ester；
The antibody copolymer preparation method of the identification tumour specific antigen of the colloid gold label is：
(1) colloidal gold solution is prepared：With the trisodium citrate aqueous solution and mass percent concentration that mass percent concentration is 1%
For 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, citric acid three by chlorauric acid solution
Sodium water solution is rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, reheats 10min, until solution is bright,
It is cooled to room temperature, the wet chemical for being then 0.075mol/L with concentration regulation pH value is 7.0, produces colloidal gold solution；
(2) in the colloidal gold solution obtained by step (1), be slowly added under magnetic stirring concentration for 30 μ g/mL be used for know
The antibody aqueous solution of other stomach cancer specific antigen, is mixed, and 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubation 23.5min,
The confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 0.65mg/mL, and addition confining liquid can avoid non-specific
Property combine, then 14000rpm centrifuges 21min under the conditions of 4 DEG C, removes supernatant, dilution is resuspended to precipitate and simultaneously washed once, obtains
Collaurum-anti-S100P protein polyclone antibodies label I, is calculated, collaurum in mass ratio:Anti- S100P protein polyclone antibodies
For 5:0.22；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 10~50 μ g/mL be used for know
The antibody aqueous solution of other liver cancer-specific antigen, collaurum-anti-S100P protein polyclone antibodies label I is prepared according to above-mentioned
Same operating method, obtains collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculates in mass ratio, colloid
Gold:Human liver cancer tissue AFU polyclonal antibodies are 5:0.265；The another colloidal gold solution taken obtained by step (1), under magnetic stirring
The antibody aqueous solution that is used to recognize colon cancer specific antigen of the concentration for 30 μ g/mL is slowly added to, colloid is prepared according to above-mentioned
The same operating method of gold-anti-S100P protein polyclone antibodies label I, obtains the antibody of collaurum-colon cancer antigen 3
(SDCCAG3) label III, calculates in mass ratio, collaurum:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.245；
(3) polymer is pressed 1:24 weight ratio is dissolved in dichloromethane, adds label I made from above-mentioned steps (2), mark
Remember thing II, label III, use ultrasonication 45s, the frequency of the ultrasonication is 35~55KHz, through ultrasonication
The polymer uniform to be formed can be made, the specificity for obtaining the identification stomach cancer, liver cancer, three kinds of tumours of colon cancer of colloid gold label resists
Former antibody copolymer.
4. a kind of can detect the composition of stomach cancer, liver cancer, colon cancer, it is characterised in that：By for recognizing that stomach cancer specificity is anti-
Former antibody, the antibody for recognizing liver cancer-specific antigen, the antibody for recognizing colon cancer specific antigen, polymer,
Colloidal gold solution is constituted；Wherein, the antibody for being used to recognize stomach cancer specific antigen is anti-S100P protein polyclone antibodies；
The antibody for being used to recognize liver cancer-specific antigen is human liver cancer tissue AFU polyclonal antibodies；It is described to be used to recognize colon cancer
The antibody of specific antigen is the antibody of colon cancer antigen 3 (SDCCAG3)；The polymer is biodegradable polymer, choosing
Autohemagglutination hydroxacetic acid, poly butyric ester, lactic acid-ethylene glycol copolymer, polylactic acid-polyethylene glycol block copolymer or poly- hydroxyl
Any one in base alkyl alcohol ester；
The antibody copolymer preparation method of the identification tumour specific antigen of the colloid gold label is：
(1) colloidal gold solution is prepared：With the trisodium citrate aqueous solution and mass percent concentration that mass percent concentration is 1%
For 0.01% aqueous solution of chloraurate, by 1.5mL:100mL volume ratio, is heated to boiling, citric acid three by chlorauric acid solution
Sodium water solution is rapidly joined wherein, and the reaction solution of stirring reaction to gained is claret, reheats 10min, until solution is bright,
It is cooled to room temperature, the wet chemical for being then 0.1mol/L with concentration regulation pH value is 8.0, produces colloidal gold solution；
(2) in the colloidal gold solution obtained by step (1), the use that concentration is 10~50 μ g/mL is slowly added under magnetic stirring
In the antibody aqueous solution of identification stomach cancer specific antigen, mix, 37 DEG C of incubation 30min, plus confining liquid continue 37 DEG C of incubations
25min, the confining liquid is the cleaning solution containing bovine serum albumin, and its mass concentration is 1mg/mL, and addition confining liquid can avoid non-
Specific binding, then 14000rpm centrifuges 22min under the conditions of 4 DEG C, removes supernatant, dilution is resuspended to precipitate and simultaneously washed once,
Collaurum-anti-S100P protein polyclone antibodies label I is obtained, is calculated in mass ratio, collaurum:Anti- S100P protein polyclones
Antibody is 5:0.23；
The another colloidal gold solution taken obtained by step (1), be slowly added under magnetic stirring concentration for 50 μ g/mL be used for recognize liver
The antibody aqueous solution of cancer specific antigen, to prepare collaurum-anti-S100P protein polyclone antibodies label I same according to above-mentioned
Operating method, obtain collaurum-human liver cancer tissue AFU polyclonal antibodies label II, calculate in mass ratio, collaurum:People
Liver cancer tissue AFU polyclonal antibodies are 5:0.28；The another colloidal gold solution taken obtained by step (1), it is slow under magnetic stirring to add
Enter concentration for 50 μ g/mL be used for recognize the antibody aqueous solution of colon cancer specific antigen, according to the above-mentioned collaurum-anti-of preparing
The same operating method of S100P protein polyclone antibodies label I, obtains the antibody of collaurum-colon cancer antigen 3 (SDCCAG3)
Label III, is calculated in mass ratio, collaurum:The antibody of colon cancer antigen 3 (SDCCAG3) is 5:0.26；
(3) polymer is pressed 1:30 weight ratio is dissolved in dichloromethane, adds label I made from above-mentioned steps (2), mark
Remember thing II, label III, use ultrasonication 60s, the frequency of the ultrasonication is 55KHz, can be with through ultrasonication
Make the polymer uniform to be formed, obtain the identification stomach cancer, liver cancer, the specific antigen of three kinds of tumours of colon cancer of colloid gold label
Antibody copolymer.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710701492.0A CN107505458B (en) | 2015-11-16 | 2015-11-16 | A kind of composition can detecte gastric cancer, liver cancer, colon cancer |
| CN201710701465.3A CN107462722B (en) | 2015-11-16 | 2015-11-16 | It is a kind of for detecting the composition of tumour |
| CN201510789097.3A CN105353127B (en) | 2015-11-16 | 2015-11-16 | A kind of composition that can detect kinds of tumors and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510789097.3A CN105353127B (en) | 2015-11-16 | 2015-11-16 | A kind of composition that can detect kinds of tumors and its application |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710701492.0A Division CN107505458B (en) | 2015-11-16 | 2015-11-16 | A kind of composition can detecte gastric cancer, liver cancer, colon cancer |
| CN201710701465.3A Division CN107462722B (en) | 2015-11-16 | 2015-11-16 | It is a kind of for detecting the composition of tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105353127A CN105353127A (en) | 2016-02-24 |
| CN105353127B true CN105353127B (en) | 2017-10-20 |
Family
ID=55329131
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710701492.0A Expired - Fee Related CN107505458B (en) | 2015-11-16 | 2015-11-16 | A kind of composition can detecte gastric cancer, liver cancer, colon cancer |
| CN201710701465.3A Expired - Fee Related CN107462722B (en) | 2015-11-16 | 2015-11-16 | It is a kind of for detecting the composition of tumour |
| CN201510789097.3A Expired - Fee Related CN105353127B (en) | 2015-11-16 | 2015-11-16 | A kind of composition that can detect kinds of tumors and its application |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710701492.0A Expired - Fee Related CN107505458B (en) | 2015-11-16 | 2015-11-16 | A kind of composition can detecte gastric cancer, liver cancer, colon cancer |
| CN201710701465.3A Expired - Fee Related CN107462722B (en) | 2015-11-16 | 2015-11-16 | It is a kind of for detecting the composition of tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN107505458B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111751555A (en) * | 2020-07-07 | 2020-10-09 | 上海怡珏生物科技有限公司 | Application of H factor antibody in preparation of detection kit |
| GB2617621A (en) * | 2022-04-16 | 2023-10-18 | Uk Nivd Ltd | Detector |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011956A (en) * | 1988-06-27 | 1991-04-30 | Ford Warren T | Polymer latexes containing metal ions and complexes |
| US6121425A (en) * | 1994-07-29 | 2000-09-19 | Nanoprobes, Inc. | Metal-lipid molecules |
| EP1383597A4 (en) * | 2001-04-30 | 2006-09-06 | Postech Foundation | Colloid solution of metal nanoparticles, metal-polymer nanocomposites and methods for preparation thereof |
| ZA200703604B (en) * | 2004-10-21 | 2009-10-28 | Pharma Diagnostics M V | Stable metal/conductive polymer composite colloids and methods for making and using the same |
| CN101750491A (en) * | 2008-12-16 | 2010-06-23 | 陈洁 | Cancer saliva rapid detection reagent |
| CN101865913B (en) * | 2009-04-16 | 2013-04-03 | 上海荣盛生物药业有限公司 | Composition for detecting rheumatoid arthritis immune antibody by lateral chromatography |
| CN102023219B (en) * | 2009-09-22 | 2013-06-19 | 上海荣盛生物药业有限公司 | Composition for detecting rheumatoid arthritis immune antibody by colloidal gold lateral chromatography |
| RU2014122048A (en) * | 2011-11-16 | 2015-12-27 | Онкомед Фармасьютикалс, Инк. | HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR APPLICATION |
| CN104142399B (en) * | 2013-05-08 | 2016-03-02 | 北京美康生物技术研究中心有限责任公司 | A kind ofly utilize colloidal gold immunochromatographimethod technology quantitatively test strips detecting Serum Pepsinogen and its preparation method and application |
| CN104280548A (en) * | 2013-07-08 | 2015-01-14 | 电子科技大学 | Carcinoembryonic antigen (CEA) rapid simple detection kit and making and application methods thereof |
-
2015
- 2015-11-16 CN CN201710701492.0A patent/CN107505458B/en not_active Expired - Fee Related
- 2015-11-16 CN CN201710701465.3A patent/CN107462722B/en not_active Expired - Fee Related
- 2015-11-16 CN CN201510789097.3A patent/CN105353127B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107462722B (en) | 2019-10-11 |
| CN105353127A (en) | 2016-02-24 |
| CN107462722A (en) | 2017-12-12 |
| CN107505458B (en) | 2019-03-12 |
| CN107505458A (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI293113B (en) | Magnetic nanoparticles with fluorescent and specific targeting functions | |
| CN104650234B (en) | Anti- AKR1B10 protein monoclonal antibodies and its application | |
| CN104316683B (en) | For the ovarian cancer cell detection kit of whole blood | |
| CN105353127B (en) | A kind of composition that can detect kinds of tumors and its application | |
| CN107677806B (en) | The preparation and detection method of the highly sensitive visualization joint inspection immuno-chromatographic test paper strip of fluorescent quantitation based on magnetic enrichment | |
| CN110514489A (en) | A kind of biological coating and preparation method thereof of the specific whole blood capture circulating tumor cell for cancer surveillance | |
| CN109061165A (en) | A kind of immune chromatography test paper, detection method and the application of nipple discharge CEA detection | |
| CN105277711B (en) | A kind of enzyme linked immunological kit for being used to detect HE4 | |
| CN109557311A (en) | The testing product and its application of diagnosis of colorectal carcinoma marker and colorectal cancer | |
| CN110331199A (en) | For detecting the molecular probe and detection method of CLDN18.2 gene expression | |
| CN110187111A (en) | One kind being used for early cardiac cancer screening ELISA kit | |
| CN111077312B (en) | Application of group of tumor-associated antigens in preparation of cardiac cancer early screening kit | |
| CN113862353A (en) | M of total RNA of peripheral blood immune cells6Application of detection reagent for A modification level in preparation of colorectal cancer diagnosis product | |
| WO2023104059A1 (en) | Circulating tumor cell detection material, detector and detection method | |
| CN104360062B (en) | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared | |
| CN104849449B (en) | Application of the enzyme labelled antibody gold nano-probe in diaminobenzidine catalyzed coloration and dark-field imaging | |
| CN112763713B (en) | Kit for detecting urothelial cancer by virtue of Neu5Gc for identifying modified UMOD in urine based on LIP | |
| CN107228938B (en) | A kind of quantitative detecting method of folic acid functionalized SiO 2 targeted nano pharmaceutical carrier | |
| CN109580951A (en) | The kit and its application method of multispecific antibody joint-detection early liver cancer marker | |
| CN109239332A (en) | A kind of kit of auxiliary detection sub-health population cancer base antigen | |
| CN108414756A (en) | Preparation method that is a kind of while detecting the protein chip of four bladder carcinoma markers in urine | |
| CN109975548A (en) | Application of the IgG4 detection reagent in terms of preparing diagnosis of colorectal carcinoma agent | |
| CN102435740A (en) | Kit for quantitative measurement of squamous cell carcinoma antigen (SCC) and its detection method | |
| CN108680750A (en) | The ELISA detection method and kit of TROP2 expressing quantities | |
| CN112129954A (en) | Application of MMP7, CTSE or LAMC2 protein in preparation of intrahepatic cholangiocellular carcinoma diagnostic reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Jiake Inventor after: Wu Kun Inventor after: Xu Liwan Inventor before: Jiang Aiying |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170830 Address after: 510663 Guangdong city of Guangzhou province Tianhe District Ling Road No. 61 building twenty-eighth room D2-101 Applicant after: Cum regenerative medical science and Technology Co Ltd Applicant after: Guangzhou Wande and match Gene Technology Co Ltd Address before: 257399 Shandong city of Dongying Province River Road No. 287, building 2, unit 1, Room 501 Applicant before: Jiang Aiying |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171020 Termination date: 20181116 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |